A groundbreaking NHS-funded research project is launching to determine whether weight-loss medications commonly used for diabetes and obesity could help women with polycystic ovary syndrome (PCOS), a hormonal condition that affects up to one in ten women of reproductive age. Dr. Shagaf Bakour, a gynaecologist at Aston University, has secured £60,000 in research funding to investigate how GLP-1 receptor agonists, including medications like Ozempic (semaglutide) and Mounjaro (tirzepatide), might improve both metabolic health and fertility outcomes in women with PCOS .

What Is PCOS and Why Does It Matter for Women?

PCOS is a common endocrine disorder that disrupts how the ovaries function, causing a cascade of symptoms that extend far beyond reproductive health. The condition affects approximately one in ten women of reproductive age and can significantly impact quality of life and long-term health outcomes . Women with PCOS often experience irregular menstrual periods, difficulty conceiving, and elevated levels of male hormones called androgens, which can trigger acne and excess hair growth. Beyond these visible symptoms, PCOS carries serious metabolic risks .

• Reproductive Effects: PCOS makes it harder to get pregnant and causes irregular periods due to hormonal imbalances.
• Metabolic Complications: Women with PCOS are more likely to develop insulin resistance, obesity, type 2 diabetes, and heart and circulation problems.
• Cosmetic Symptoms: Higher androgen levels lead to acne and unwanted hair growth that can affect self-esteem.

The metabolic component of PCOS is particularly important because it means many women with the condition struggle with weight management and face elevated cardiovascular risk. This is where GLP-1 receptor agonists enter the picture as a potential treatment avenue .

How Could Weight-Loss Drugs Help Women With PCOS?

GLP-1 receptor agonists are medications originally developed to help people with type 2 diabetes control blood sugar levels, but they've gained widespread attention for their weight-loss effects. These drugs work by mimicking a natural hormone in the body that regulates appetite and blood sugar. For women with PCOS, the appeal goes beyond simple weight loss. Since PCOS is fundamentally linked to insulin resistance and metabolic dysfunction, medications that improve insulin sensitivity and reduce weight could theoretically address the root causes of the condition rather than just treating symptoms .

Dr. Bakour and her multidisciplinary team, working alongside Dr. Hoda Harb, a consultant obstetrician and gynaecologist at Sandwell and West Birmingham NHS Trust, will investigate whether these medications can improve both general health and fertility outcomes in women with PCOS. The research is being conducted through the Sandwell and West Birmingham NHS Research Fellowship scheme, which supports projects connecting frontline clinicians with academic partners to enhance patient care .

What Will This Research Actually Involve?

The study is structured in multiple phases to build evidence systematically. Initially, the research team will conduct a comprehensive review of existing evidence about GLP-1 receptor agonists in PCOS treatment. This phase will identify what is already known, pinpoint important gaps in current knowledge, and determine which health outcomes matter most to both women living with PCOS and the clinicians treating them .

Following this evidence review, the team will work toward securing the necessary ethical approvals and governance clearances. The next stage involves a real-world feasibility study that will link fertility services, general practice records, and weight-management clinics to assess how these medications actually perform in clinical practice. This approach is crucial because it will show whether GLP-1 drugs could lead to more consistent and coordinated care for women with PCOS across different healthcare settings .

Why Is This Research Needed Now?

Despite affecting millions of women, PCOS remains inconsistently managed across the UK healthcare system. Women with the condition often receive different advice and treatment options depending on which clinic or specialist they see, leading to fragmented care and missed opportunities for early intervention. The current lack of standardized treatment pathways means some women struggle for years before receiving an accurate diagnosis or appropriate management strategy .

"The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care. The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways. Currently, care can vary, and women do not always get the same advice or treatment options," said Dr. Shagaf Bakour.

Dr. Shagaf Bakour, Gynaecologist and Director of Medical Education at Aston Medical School

This research could address a critical gap in women's healthcare. By establishing whether GLP-1 drugs can effectively treat PCOS, the study may lead to earlier intervention, better long-term health outcomes, and more joined-up care across fertility services, primary care, and weight-management clinics .

What Could This Mean for Women With PCOS?

If the research demonstrates that GLP-1 receptor agonists are effective for PCOS, it could transform treatment options for millions of women. Rather than managing individual symptoms with multiple medications, women might have access to a single drug that addresses the underlying metabolic dysfunction driving the condition. This could improve fertility prospects for women trying to conceive, reduce the risk of developing diabetes and heart disease, and help with weight management, which is often a frustrating challenge for PCOS patients .

Professor Elizabeth Hughes, director of research and development at Sandwell and West Birmingham NHS Trust, emphasized the importance of this work for advancing women's healthcare. The research team is committed to producing published evidence that will support further funding and help prevent long-term health complications linked to PCOS .

How to Stay Informed About PCOS Treatment Options

• Talk to Your Doctor: If you have PCOS or suspect you might, discuss current treatment options with your GP or gynaecologist, including whether you might be a candidate for emerging therapies as evidence develops.
• Track Your Symptoms: Keep a record of irregular periods, weight changes, and other PCOS symptoms to share with your healthcare provider, which helps with diagnosis and monitoring treatment effectiveness.
• Follow Research Updates: Watch for published results from this NHS study and other PCOS research, as findings will likely influence clinical guidelines and treatment recommendations over the next few years.

The research is expected to produce published evidence that will inform clinical practice and potentially reshape how PCOS is treated in the UK and beyond. For women living with this common but often overlooked condition, this study represents a meaningful step toward more effective, consistent, and evidence-based care .